HANALL BIOPHARMA CO.,LTD
Financials
Valuation Metrics
HANALL BIOPHARMA CO.,LTD's Market Cap is ₩2.1T. At end of 2025 it was ₩2.3T. Ranked #193 of 2,417 in KR market (top 8%), #160 of 781 on KOSPI (top 20%), #13 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 6%) by Market Cap.
Investment Metrics(as of 2026-10-15)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 2.14T KRW | KR#193/2,417 Sec#13/231 |
| Revenue | 162.66B KRW | KR#1,133/2,417 Sec#67/231 |
| Net Income | -24.90B KRW | KR—/2,417 Sec—/231 |
| Total Assets | 240.51B KRW | KR#1,169/2,417 Sec#82/231 |
| Net Assets | 161.63B KRW | KR#1,089/2,417 Sec#77/231 |
| Employees | 318 | KR#756/2,417 Sec#65/231 |
| Value | ||
| P/B | 13.22x | KR#2,383/2,417 Sec#218/231 |
| P/S | 13.14x | KR#2,301/2,417 Sec#172/231 |
| EV/EBITDA | 450.91x | KR#1,552/2,417 Sec#109/231 |
| FCF Yield | -0.15% | KR—/2,417 Sec—/231 |
| Profitability | ||
| ROE | -15.41% | KR#2,027/2,417 Sec#154/231 |
| ROA | -10.35% | KR#2,112/2,417 Sec#161/231 |
| Op. Margin | 2.93% | KR#1,259/2,417 Sec#91/231 |
| Revenue Growth | 8.38% | KR#990/2,417 Sec#97/231 |
| Earnings Growth | -1215.12% | KR#1,330/2,417 Sec#95/231 |
| Financial Health | ||
| Debt Ratio | 48.81% | KR#944/2,417 Sec#107/231 |
| Total Debt | 44.09B KRW | KR#1,050/2,417 Sec#72/231 |
| FCF | -3.29B KRW | KR#1,408/2,417 Sec#112/231 |
| Cash | 30.20B KRW | KR#1,007/2,417 Sec#69/231 |
| Current Ratio | 1.49x | KR#1,207/2,417 Sec#130/231 |
| Net Debt/EBITDA | 2.91x | KR#907/2,417 Sec#66/231 |
| Performance | ||
| 1Y Return | 18.21% | KR#429/2,417 Sec#24/231 |
| 1M Return | -15.84% | KR#2,181/2,417 Sec#207/231 |
| From 52W High | -43.97% | KR#1,000/2,417 Sec#69/231 |
| 1Y MDD | -44.84% | KR#766/2,417 Sec#60/231 |
| Trading | ||
| Volume | 150,402 shares | KR#479/2,417 Sec#49/231 |
| Trading Value | 6.11B KRW | KR#256/2,417 Sec#21/231 |
| Foreign Own. | 3.92% | KR#1,066/2,417 Sec#96/231 |
| Per Share | ||
| EPS | -477 KRW | KR—/2,417 Sec—/231 |
| BPS | 3,094 KRW | KR#1,851/2,417 Sec#138/231 |
Company Info
Hanall Biopharma is a pharmaceutical company established in 1973 and listed on the Korea Exchange in 1989. It manages overseas clinical trials and licensing for new drugs through its U.S. subsidiary, HPI. The company manufactures and sells over 160 pharmaceutical products for endocrine, circulatory, and other systems, while researching diverse new drugs, including antibody-based therapies for autoimmune diseases. By strengthening its R&D infrastructure with First-in-Class biosimilar drug research, dedicated personnel, and expanded facilities, Hanall Biopharma is enhancing its global market competitiveness. It is headquartered in Daedeok-gu, Daejeon.